Federation Bio, a South San Francisco, CA-based microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, closed a $50m Series A financing.
Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.
The company will use proceeds from the financing to build out its in-house development process to enable Phase 1/2 manufacturing and advance its lead program into the clinic.
Founded by Michael Fischbach, Ph.D., and Dylan Dodd, M.D., Ph.D., with support from Venrock, Federation Bio is pioneering new approaches for treating intractable diseases by combining an unprecedented number of microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system.
The company’s lead program is focused on secondary hyperoxaluria, a condition affecting more than 200,000 Americans, with the goal of entering the clinic in 2022.
Federation Bio also announced today the appointment of Emily Drabant Conley, Ph.D., as chief executive officer taking over from Venrock partner and founding CEO Racquel Bracken, as well as the additions of both Dr. Conley and John Stuelpnagel, D.V.M, to the Federation Bio board of directors.
Dr. Conley and Dr. Stuelpnagel join Bracken, Dr. Fischbach, Bryan Roberts, Ph.D., of Venrock, and Patrick Zhang of Horizons Ventures on the Federation Bio board of directors. Dr. Fischbach and Dr. Dodd are also professors at Stanford University.